Best Websites for Pharmaceutical and Healthcare Updates

Best Pharma Websites - - Luca Dezzani

Best Pharma Websites - - Luca Dezzani

The rapidly changing environment of pharmaceutical and biotechnology industries and the need to keep pace with the constantly evolving business have driven large- and small-scale pharma companies, professionals, and consumers to continuously seek answers to certain questions involving latest drug development and company performance updates. Through the advancement in technology, most of these essential information can easily be searched on the internet. With just one click, facts about latest company mergers, approval of new drugs, and pharma trends and analyses can be found on the web. However, not all information retrieved from different websites are considered accurate and reliable because some of these articles lack credible resources.

According to a document published by Dalhouse University, six criteria must be followed in order to sort good websites from the bad one. These include authority, purpose, coverage, currency, objectivity and accuracy. This simply means that authorship must be clear, the site must be organized and focused to provide information to its target audience, and the content must be based on factual information and always be up-to-date (Dalhousie University).

The following will give an overview of some of the reliable websites that provide free access to the latest pharma and biotech news.

  1. New York Times

The New York Times (NYT) started its journey as a printed American daily newspaper published in New York City since September 21, 1851. Its presence in the world wide web has been recognized in the year 1996. Since then, it has been ranked as one of the top websites. In fact, the domain has recorded a total of 390.5 million visitors in October 2016. Though NYT has been known to cover a wide range of topics, particularly in business and politics, it also provides a huge amount of information in the healthcare field and the pharmaceutical industry.

  1. Forbes

Though Forbes has built its reputation in publishing original articles that focus on American business, it also gives credible information on pharmaceutical and healthcare industry particularly on investing and marketing topics. has been a part of Forbes Digital, a division of Forbes Media LLC and was tagged as the  “Home Page For The World’s Business Leaders”. Moreover, it was estimated that nearly 122 million viewers visited the site in October 2016. It also uses the ‘contributor model’ allowing a wide network of contributors to write and publish their article on the website.

  1. Pharmacy Times

Pharmacy Times provides clinically based, practical and professional information pharmacists can use in their everyday practice. Features and departments cover medication errors, drug interactions, patient education, pharmacy technology, disease state management, patient counseling, product news, pharmacy law, and health-system pharmacy. Pharmacy Times Continuing Education™ (PTCE) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. It was estimated that 690,000 viewers visited the site in October 2016.

  1. FiercePharma

Fiercepharma aims to inform a wide range of audience about the latest updates on the pharma industry. The website, together with Fiercebiotech, are actually divisions of Questex, a leading global business information company headquartered in Newton, MA. The articles generally published on Fiercepharma focus on R&D, manufacturing, marketing, and drug delivery. Aside from discussing topics related to human health, Fiercepharma also provides information related to veterinary medicine. Aside from this, the website has recorded an approximately 570,00 viewers in October 2016.

  1. PharmaTimes

Through the unique blend of news stories, interviews, features, case studies, analysis and comments, Pharmatimes’ editorial lens provide an in-depth understanding of various pharma-related topics. Pharmatimes also aims to deliver independent, solid and reliable content through unbiased, fair and educated opinion and analysis. The website has an approximately 50,000 viewers in October 2016.


The Underrated Truth Behind First Impressions


There is so much information going around about what makes a meeting or interview successful that sometimes we lose sight of the fundamentals.

As a former recruiter I had the opportunity to meet numerous different candidates; many of whom got the chance to be introduced to their desired employer and achieved their career goals. Some however struggled to demonstrate their ability.

But what factors influenced their performance?

Experience, skills and competence are the most obvious attributes to consider and are definitely the backbone of winning a new job, client or project. Let’s just call them PREPARATION. We all know the importance of these factors and we are working hard to demonstrate them. We go to networking events, put our resume on LinkedIn, list our achievements on social media and feel accomplished by doing our best.

But is that really it?

The answer is easy: no. Regardless of the technological development and the digital boom, human beings are still lead by instinct and emotions. Whenever we meet someone new, our brain forms a mental image in less than a blink of an eye based on their physical appearance, body language and facial expression. And it all happens in our subconscious, without even realizing it! Research shows that non-verbal communication influences the outcome of a meeting notably more than anything what we say. Our brain seeks for traces of attractiveness and trustworthiness unconscientiously and evaluates the personality based on the initial observation.

In other words, the moment you walk in the door you make up your mind about the other person. And that sets the tone of the entire meeting. The initial judgments will determine the flow of the conversation, because our brain will constantly seek for confirmation to prove the FIRST IMPRESSION.

How can we project trustworthiness?

  1. Dress to impress. Appropriate clothing wins half the battle for you. When you dress for the role you strive for, you naturally upgrade your behavior. And when you feel confident your body language, posture, facial expression and voice pitch will all project the same.
  2. Smile. An honest smile can open many doors. It’s a form of welcoming and a sign of friendliness and approachability.
  3. Embrace eye contact. It shows straightforwardness and sincerity and builds up tremendous trust in just few seconds!
  4. Straighten your posture. Standing tall, pulling your shoulders back and holding your head straight are all signals of confidence and competence.
  5. Step up your hand-shake game. Adjust the firmness of your handshake to the amount of pressure you are receiving from the other person. Too firm handshakes can come across as intimidating as weak ones!
  6. Adjust your behavior. Understand the environment and align your demeanor. Improper attitude can quickly sabotage your success!
  7. Be genuine. There is nothing worse than a visibly fake smile!


The bottom line is that although FIRST IMPRESSIONS are underrated sometimes, they have much bigger influence on our decisions than we think.

Veronika Nemeth is an Image Consultant and Personal Branding Strategist specialized in Pharmaceutical industry. For more information visit www.


Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) from AbbVie Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease


Nov 15, 2016

AbbVie (NYSE: ABBV), a global biopharmaceutical company has announced that 98 percent (n=102/104) of chronic hepatitis C virus (HCV) infected patients with severe chronic kidney disease (CKD) achieved sustained virologic response following 12 weeks of treatment (SVR12) with its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) in the primary intent-to-treat (ITT) analysis. These new data from the Phase 3 EXPEDITION-4 study that evaluates patients with chronic HCV infection were presented as a late-breaker at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston.

Ed Gane, M.D., professor of medicine at the University of Auckland in Auckland, New Zealand, said: “HCV patients with severe chronic kidney disease present a complex challenge for physicians to treat, particularly as kidney disease progresses, and if the patient has genotype 2 or 3 or has compensated cirrhosis. The results seen in EXPEDITION-4 are a positive development in AbbVie’s investigation of the G/P regimen for patients with chronic kidney disease, who currently have limited HCV treatment options.”

“With our investigational, pan-genotypic regimen, our goal is to provide a safe and effective cure to patients across genotypes, including patients with severe chronic kidney disease, regardless of previous treatment status or presence of compensated cirrhosis. Our clinical development program reflects our ongoing commitment to addressing treatment areas of continued unmet need,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie.

Roche launches a global network of cancer immunotherapy centers of research excellence (imCORE™)

Roche Igea Luca Dezzani

Roche Igea Luca Dezzani

15 November 2016

Roche has launched the global network of cancer immunotherapy Centers of Research Excellence (imCORE™), which will bring together many of the world’s leading scientific and clinical experts in cancer immunotherapy for collaborating in the investigation of the most promising new treatment approaches. The target is to start pre-clinical and clinical research rapidly based on the latest scientific discoveries and to aggregate and share data for accelerating the search for cures for people with cancer. The imCORE™ Network will focus on finding ways to expand the number of people who benefit from cancer immunotherapy by exploring new approaches for activating a person’s immune system to fight their cancer.

Up to 100 million Swiss Francs will be invested by Roche for supporting basic and clinical research collaborations regarding cancer immunotherapy. This investment is incremental to the on-going research and development of investigational medicines and treatment approaches of Roche in the field of cancer immunotherapy.

Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development, Roche, said: “We believe the fastest way to advance progress against cancer is through collaboration, and consistent with our values, the goal of imCORE is to facilitate access to new technologies and emerging data among the top researchers around the world. imCORE represents our most recent commitment to collaborate with the global cancer community to further understand the biology and immunology of cancer and to develop new treatments that may one day offer a cure for people with cancer.’’


European Union Gives Approval to IBRANCE® (palbociclib) for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer

Pfizer Igea Luca Dezzani

Pfizer Igea Luca Dezzani

November 10, 2016

Pfizer Inc. has announced that the European Commission (EC) has approved IBRANCE® (palbociclib) for treating women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer. The approval is for IBRANCE for using in combination with an aromatase inhibitor. It also covers the use of IBRANCE combining with fulvestrant in women who have received endocrine therapy previously.

IBRANCE is the first medicine to be approved in Europe that works by inhibiting cyclin-dependent kinases 4 and 6 (CDK 4/6). It is also the first medicine in nearly 10 years approved for treating women with this type of metastatic breast cancer in the first-line setting. Women with HR+/HER2- metastatic breast cancer represent about 60 percent of all metastatic breast cancer cases.

Andreas Penk, M.D., regional president, International Developed Markets, Pfizer Oncology, said: “Today’s approval of IBRANCE in the European Union (EU) brings an innovative and much-needed new treatment option to tens of thousands of women with HR+/HER2- metastatic breast cancer. With strong and consistent data in three pivotal clinical studies and rapid adoption as a standard of care in the U.S., IBRANCE represents a potential new benchmark for the treatment of HR+/HER2- metastatic breast cancer in Europe.”


Opdivo (nivolumab) and Yervoy (ipilimumab) Regimen Shows Promising Safety and Efficacy in Previously Treated Patients with Advanced Form of Bladder Cancer

BMS Igea Luca Dezzani

BMS Igea Luca Dezzani

November 12, 2016

Bristol-Myers Squibb Company has announced positive results from the Phase 1/2 open-label CheckMate-032 trial that investigates two combination schedules of Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with locally advanced or metastatic urothelial carcinoma (mUC) previously treated with platinum-based therapy. These data were presented during the Oral Late-breaking Abstract Session II, at the 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC) in National Harbor, Md.

Urothelial carcinoma is the most common type of bladder cancer. It accounts for approximately 90% of bladder cancer cases. Bladder cancer is the ninth most commonly diagnosed cancer in the world, with more than 165,000 deaths annually, and an estimated 430,000 new cases diagnosed per year.

Padmanee Sharma, M.D., Ph.D., study investigator and professor at The University of Texas MD Anderson Cancer Center, said: “Metastatic urothelial carcinoma is an area of significant unmet medical need, especially for patients in the advanced stages of the disease who have progressed on standard chemotherapy. Earlier this year, we presented encouraging results from this trial for Opdivo monotherapy, and now we are seeing the promise of a combination regimen with Opdivo and Yervoy for previously treated patients with this common type of advanced bladder cancer. These findings support the need for further study of combination therapy to assess outcomes and potential survival in patients with metastatic urothelial carcinoma.”

“These results from the CheckMate -032 study support further development of the Opdivo plus Yervoy regimen for treatment of metastatic urothelial carcinoma in platinum refractory patients. The findings also bolster our belief that combining our Immuno-Oncology agents, Opdivo and Yervoy, can potentially advance cancer care,” commented Vicki Goodman, M.D., development lead, Melanoma and Genitourinary Cancers, Bristol-Myers Squibb.

The World’s Most Reputable Pharmaceutical Companies 2016

World's 12 Most Reputable Pharmaceutical - - Luca Dezzani

Customers’ satisfaction is immensely important for the pharmaceutical companies. When these companies focus on innovation and act responsibly, they gain the required trust from the customers all over the world. Based on how good people feel about big pharma, a ranking has been published by the Reputation Institute (RI). Based on the ranking, we have chosen the following top 10 pharmaceutical companies:

World's 12 Most Reputable Pharmaceutical - - Luca Dezzani

  1. Bayer

Bayer is a German pharmaceutical and life science company which is headquartered in the city of Leverkusen. The company was founded in 1873. The pharmaceutical division of the company focuses on prescription drugs for women’s healthcare and cardiology. It also concentrates on specialty therapeutics in the areas of hematology, oncology, and ophthalmology. Its annual revenue in 2015 was $52 billion.

  1. Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Illinois, United States. In 2015, its annual revenue was $20.4 billion. The company is trying to help people lead healthier lives by creating breakthrough products in branded generic pharmaceuticals, diagnostics, nutrition, and medical devices. More than 74,000 people work in this company, and it is operating in over 150 countries.

  1. Novo Nordisk

Novo Nordisk is a prominent healthcare company which is headquartered in Denmark. The company has been focusing on diabetes care for the last 90 years. The company is also trying to help people defeat different other serious diseases like haemophilia, obesity, and growth disorders. The company has branches in 75 countries, with 42,600 employees. Its annual revenue was $16.05 billion in 2015.

  1. Roche

Roche was founded in 1896 in Basel, Switzerland. Since then, the company has been actively trying to improve the lives of millions of people globally through innovative medicines and diagnostic tests. It was a pioneer company to deliver personalized healthcare to patients. It is also the global leader in cancer treatment. Around 90,000 people work in this company, which operates in more than 100 countries. In 2015, its annual revenue was $50 billion.

  1. Merck

Merck is one of the largest pharmaceutical companies in the world with a 125-year history. It is currently operating in more than 140 countries, with its headquarter in New Jersey, United States. In 2015, its annual revenue was $39.5 billion. The company is now focusing on diabetes, oncology, vaccines, and animal health.

  1. Sanofi

Sanofi is a global life sciences company with more than 110,000 employees. The company is trying to make a difference in patient’s daily life by transforming scientific innovation into healthcare solutions. The focus areas of the company include oncology, multiple sclerosis, diabetes, cardiovascular diseases, and human vaccines. The company has presence in more than 100 countries. Its annual revenue in 2015 was $40.5 billion.

  1. Allergan

Allergan is a global leader in Growth Pharma which is headquartered in Dublin, Ireland. The company is committed to developing products in the area of gastroenterology, women’s health, urology, central nervous system, medical aesthetics, eye care, and dermatology. The company has commercial operations in 100 countries, and 16,000 people work for this company. Its annual revenue was $18.8 billion in 2015.

  1. AstraZeneca

AstraZeneca is a global biopharmaceutical company headquartered in London, United Kingdom. The innovative medicines of the company are used by millions of patients around the world. Focus areas of the company include cardiovascular and metabolic disease, oncology, respiratory, inflammation and autoimmunity, and neuroscience. Its annual revenue was $24.71 in 2015.

  1. Eli Lilly and Company

Eli Lilly is a renowned pharmaceutical company that has been working with success for the last 140 years. It is headquartered in Indiana, America. Its business areas include oncology, bio-medicines, diabetes, and animal health. Approximately 42,000 people work for this company around the world. Its net income in 2015 was $24 billion.

  1. AbbVie

AbbVie is a global pharmaceutical company based in Illinois, United States. The company develops new drugs in several therapeutic areas, including immunology, liver disease, kidney disease, oncology, neuroscience, and women’s health. With more than 28,000 employees, the company is currently operating over 170 countries. Its annual revenue in 2015 was $22.8 billion.

11. GlaxoSmithCline

GlaxoSmithCline is a British pharmaceutical company with a mission to help people feel better and live longer. The company manufactures innovative medicines, consumer healthcare products, and vaccines. The total turnover of the company in the pharmaceuticals sector was $14.2 billion in 2015. With more than 38,000 employees, the company is currently operating in 52 countries. The focus areas of the company includes oncology, HIV infections, respiratory diseases, and immune-inflammation.

12. Novartis

Novartis is a Switzerland-based global healthcare company. The company mainly focuses on innovative patented medicines, generics and eye care devices. In particular, the company is committed to fulfill the medical needs of people with cancer and related diseases. In 2015, the company achieved the net sales of $49.4 billion. Approximately 118,000 people work for Novartis, and the products of the company are available in over 180 countries.



Pfizer Announces Results from Phase 3 OPAL Clinical Development Program Investigating XELJANZ® (Tofacitinib Citrate) for Psoriatic Arthritis

Pfizer Igea Luca Dezzani

Pfizer Igea Luca Dezzani

November 15, 2016

Pfizer Inc. has announced that new results from the Phase 3 Oral Psoriatic Arthritis TriaL(OPAL) studies, Broaden and Beyond, will be presented at the ACR/ARHP Annual Meeting 2016, which will be held in November 11-16, in Washington, DC. OPAL Broaden and OPAL Beyond evaluated the safety and efficacy of XELJANZ® (tofacitinib citrate) in adult patients with active psoriatic arthritis (PsA). These patients had an inadequate response (IR) to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or to tumor necrosis factor inhibitors (TNFis), respectively. OPAL Broaden and OPAL Beyond met their primary efficacy endpoints that revealed a statistically significant improvement with tofacitinib 5 mg and 10 mg twice daily (BID). Detailed results from OPAL Broaden will be presented during a plenary session for the first time at ACR/ARHP. Additionally, results from OPAL Beyond will be presented during a late-breaking abstract poster session.

Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development, said: “Psoriatic arthritis is a chronic condition that can have a significant and potentially debilitating impact on people with the disease, who currently have limited treatment options. As the only JAK inhibitor being investigated in psoriatic arthritis, tofacitinib, if approved, would provide patients and healthcare professionals the first medicine in a new class to treat this disease. We continue to progress the OPAL clinical development program globally and look forward to possible future regulatory filings.”

Secret weapon to success

Happy Successful Business People Celebrating and Jumping in New

In today’s corporate world stakes are real high to perform. As a leader, you are constantly challenged regardless of your career level; yet not everyone will have a thriving professional progress.

But what’s the difference between successful and average?

Whether you are starting out your career, are an aspiring manager or an established leader, there is always a way to be better.   Life is about connections both personally and online, and those who are clear about what they stand for are able to connect with their audience on a much higher emotional level. You may have experienced already that professionals who take time to consciously develop their personal brand, tend to have a much greater influence on their teams and colleagues.

Over the course of your career there are countless situations where you are required to manifest your values and demonstrate your leadership skills. Appearance, behavior and communication play a very important role in presenting yourself and certainly make a difference in how others perceive you. But without a real understanding of your personal ‘why’, your life purpose and your unique quality, your self-image tend to cause dissonance, perplexity and insecurity. With that said, it’s safe to state that the real secret of dominating leaders is clarity about their self- identity. When you are able to master self-awareness and be your best self on the inside, it becomes incredibly easy to align your external image with it and your audience will automatically resonate with your charisma.

If you would like to take the leap and start building a strong professional image, I recommend you to analyze the following areas. 

  1. Understand what your real passions are. Think about activities, situations or challenges that excite you.
  2. Identify your most important personal attributes. Think about how others describe you as a person at work or in personal life.
  3. Get clear on your top skills and greatest strengths. Think about things that benefitted you along your career.
  4. Find out what differentiates you from the competition. Everyone has something to offer that no one else does. Dig deep to understand what makes the real difference. 
  5. Once you gained clarity on who you are figure out what kind of leader/professional do you want to be and which areas do you need to improve to get there. Recognize the gap and identify your personal ‘why’.

This little exercise will give you a much better understanding of yourself and your current situation and will trigger a higher level of self-awareness in your life and career.


Veronika Nemeth

Image Consultant & Personal Branding Strategist                  

For more info visit:

Bristol-Myers Squibb and Enterome Announce Immuno-Oncology Collaboration Focused on Microbiome-Derived Biomarkers, Bioactive Molecules, and Drug Targets


November 16, 2016

Bristol-Myers Squibb Company and Enterome, a pioneer in developing pharmaceuticals and diagnostics based on the gut microbiome, announced that they have entered into an Immuno-Oncology focused collaboration agreement for discovering and developing microbiome-derived biomarkers, bioactive molecules, and drug targets. These will be developed as potential companion diagnostics and therapeutics for cancer. Furthermore, through this collaboration, efforts will be made for identifying novel microbiome-derived biomarkers in order to improve clinical outcomes for patients treated with Bristol-Myers Squibb’s Immuno-Oncology portfolio.

Carl Decicco, Ph.D., head of discovery at Bristol-Myers Squibb, said: “We continue to pursue the full potential of Immuno-Oncology by applying rapidly evolving science, technology and research to our strong foundation in harnessing the immune system to fight cancer. Business development has been integral in partnering external innovation with our internal R&D expertise and capabilities. Enterome’s focus on target identification and validation along with their significant experience in microbiome research can help to advance our goal to improve outcomes for patients treated with immunotherapies.”

“We are delighted to collaborate with Bristol-Myers Squibb to help advance the field of Immuno-Oncology. The exciting combination of Bristol-Myers Squibb’s extensive capabilities in Immuno-Oncology with our expertise in identifying novel targets and molecules derived from the gut microbiome is highly complementary, and offers a unique opportunity to develop a new generation of cancer drugs and diagnostics,” said Pierre Belichard, chief executive officer at Enterome.